Biphenotypic sinonasal sarcoma with PAX3::MAML3 fusion transforming into high-grade rhabdomyosarcoma: report of an emerging rare phenomenon

Virchows Arch. 2023 Apr;482(4):777-782. doi: 10.1007/s00428-023-03501-0. Epub 2023 Jan 31.

Abstract

We report a case of a 67-year-old male patient with a sinonasal tumor that showed areas of classic biphenotypic sinonasal sarcoma (BSNS) which in some sections sharply transitioned into high-grade rhabdomyosarcoma. Immunohistochemically, the conventional BSNS parts showed S100 protein, SMA, PAX7, and focal MyoD1 expression, whereas desmin and myogenin were negative. In contrast, the cells in high-grade areas expressed desmin, MyoD1, myogenin, and PAX7, while being negative for S100 protein and SMA. Using the Archer FusionPlex assay, the classical PAX3::MAML3 gene fusion was detected. FISH for PAX3 and MAML3 confirmed a break of these genes in both components. Despite aggressive therapy, the tumor progression resulted in the patient's death. The herein presented case, together with 2 previously published cases of BSNS with high-grade transformation, helps to better understand this novel phenomenon. Although the risk for such transformation appears low, it has important clinical and diagnostic implications which are discussed.

Keywords: Biphenotypic sinonasal sarcoma; High-grade transformation; PAX3::MAML3; Rhabdomyosarcoma.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers, Tumor / genetics
  • Desmin
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Myogenin
  • PAX3 Transcription Factor / genetics
  • Paranasal Sinus Neoplasms* / pathology
  • Rhabdomyosarcoma* / genetics
  • Rhabdomyosarcoma, Alveolar*
  • S100 Proteins
  • Sarcoma* / genetics
  • Soft Tissue Neoplasms* / genetics
  • Trans-Activators

Substances

  • Biomarkers, Tumor
  • Desmin
  • MAML3 protein, human
  • Myogenin
  • PAX3 protein, human
  • PAX3 Transcription Factor
  • S100 Proteins
  • Trans-Activators